Compare RL & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RL | EXAS |
|---|---|---|
| Founded | 1967 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 19.3B |
| IPO Year | 1997 | N/A |
| Metric | RL | EXAS |
|---|---|---|
| Price | $363.59 | $102.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 19 |
| Target Price | ★ $383.80 | $81.27 |
| AVG Volume (30 Days) | 526.7K | ★ 2.3M |
| Earning Date | 02-05-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 28.75 | N/A |
| EPS | ★ 13.54 | N/A |
| Revenue | ★ $7,570,600,000.00 | $3,082,033,000.00 |
| Revenue This Year | $13.04 | $19.40 |
| Revenue Next Year | $5.07 | $13.51 |
| P/E Ratio | $26.82 | ★ N/A |
| Revenue Growth | 12.32 | ★ 14.47 |
| 52 Week Low | $176.61 | $38.81 |
| 52 Week High | $380.00 | $102.66 |
| Indicator | RL | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 84.47 |
| Support Level | $358.76 | $101.51 |
| Resistance Level | $373.87 | $102.56 |
| Average True Range (ATR) | 8.42 | 0.34 |
| MACD | -0.31 | -0.65 |
| Stochastic Oscillator | 53.14 | 85.71 |
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.